Biotech Values

[DewDiligence]

ARTE – This could get ugly (literally): faces will be
treated with ArteFill on one side and another dermal
filler on the other side. Please see the bottommost
paragraph of this PR. ARTE seeks more and more
desperate ways to promote a product nobody wants, IMO.

http://biz.yahoo.com/bw/071029/20071029006466.html?.v=1

>>
Dr. Stacy Smith Launches Study to Test Duration, Safety and Patient Preference for Dermal Fillers for the Treatment of Smile Lines

Monday October 29, 4:45 pm ET

Study Compares ArteFill, Radiesse and Restylane

SAN DIEGO--(BUSINESS WIRE)--Leading San Diego, CA – based dermatologist Dr. Stacy Smith announced today he is conducting a head-to-head clinical study comparison of dermal fillers – ArteFill, Radiesse and Restylane. This 24 patient study will evaluate nasolabial fold, or smile line wrinkle correction over a two year period.

Stacy R. Smith, MD, President, Therapeutics Clinical Research, Assistant Clinical Professor of Dermatology, University of California San Diego, Division of Dermatology, is conducting this “split-face” study whereby patients will receive ArteFill on one side of their face and will receive a temporary dermal filler, either Restylane or Radiesse on the other. Every three months, photographs will be taken to allow a blinded evaluation of the patients’ level of wrinkle correction. Patients will also be asked to provide their assessment of wrinkle correction and level of satisfaction with the treatment on each side of their face. These patients will be followed for a total of two years and the possibility of announcing interim results will be assessed throughout the study. When one of the smile lines returns to baseline, the patient will have the option to cross over and receive ArteFill on the “temporary filler treated” side of their face for full wrinkle correction.

Dr. Smith expects to enroll 24 patients by the end of March 2008. A patient satisfaction survey along with patient photos of the results are part of the study protocol. After study completion, these findings will be submitted and are expected to be published in a peer reviewed dermatology journal.

“I am looking forward to conducting this study to provide valuable information comparing the temporary fillers with ArteFill. ArteFill has shown persistence up to 5 years in recently published results. A direct comparison will better illuminate the differences in performance and patient preference between ArteFill and the temporary fillers. Both physicians and consumers need this kind of information to make better informed decisions regarding their choice of a dermal filler,” said Dr. Smith. For more information on Dr. Smith or his study, please call [[phone] or visit www.therapeuticsresearch.com ]

Dr. Smith received a research grant from Artes Medical, Inc. (NASDAQ: ARTE ) to conduct this study.
<<